Study ATYR1940-C-002 is a multi-national, multi-center, double-blind, randomized, placebo-controlled, ascending dose study designed to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamic effects of ATYR1940 in patients with FSHD. Up to 44 patients are planned to be enrolled at multiple study centers in the U.S. and Europe; the actual number of patients enrolled will depend on the number of cohorts initiated.